| Title | Date | Affymetrix Reports Fourth Quarter and Fiscal Year 2009 Results| Company reports total revenue of $88.8 million and net income of $2.8 million for Q4SANTA CLARA, Calif., Feb 03, 2010 (BUSINESS WIRE) -- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2009. Total revenue for the fourth quarter was $88.8 million, as compared to total revenue of $78.6 million in the fourth quarter of 2008. In constant currency terms, revenue for the fourth quarter 2009 was positively impacted by $2.6 ... |
| 02/03/10 | Affymetrix to Host Conference Call on February 3, 2010 to Announce Fourth Quarter and Fiscal 2009 Results| SANTA CLARA, Calif., Jan 20, 2010 (BUSINESS WIRE) -- Affymetrix, Inc. (Nasdaq: AFFX) today announced that it will release operating results for the fourth quarter and fiscal year 2009 after close of the stock market on Wednesday, February 3, 2010.
Affymetrix' management team will host a conference call on February 3, 2010 at 2:00 P.M. PT to review its operating results. A live webcast can be accessed by visiting the Investor Relations section of http://www.affymetrix.com. Investors and other i... |
| 01/20/10 | Affymetrix to Present at the 28th Annual J.P. Morgan Healthcare Conference| SANTA CLARA, Calif., Dec 23, 2009 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ: AFFX) today announced that Kevin M. King, President and Chief Executive Officer, will provide a company overview at the J.P. Morgan Healthcare Conference on January 14 in San Francisco. A live webcast of the presentation will take place at 9:00 A.M. PT.
To access the live and archived webcasts, please visit www.affymetrix.com and click on the "Webcast Archive" link in the "Investors" section. An archived webcast of ... |
| 12/23/09 | FDA Grants Emergency Use Authorization for TessArae(R) 2009 H1N1 Influenza A Virus Assay Based on the Affymetrix(R) GeneChip(R) Platform| FDA Authorizes Emergency Use of Assay for the Detection and Differentiation of the 2009 H1N1 Influenza A VirusSANTA CLARA, Calif. & POTOMAC FALLS, Va., Dec 21, 2009 (BUSINESS WIRE) -- TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray(R) Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza ... |
| 12/21/09 | Affymetrix Appoints Andrew Last to Chief Commercial Officer| SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 7, 2009--
Affymetrix, Inc. (Nasdaq: AFFX) announced today the addition of Andrew
J. Last, PhD, to its management team as Chief Commercial Officer.
“Andy is a proven leader in our core business as well as in the
downstream markets of validation and routine testing,” said Kevin King,
president and CEO of Affymetrix. “He will drive our commercial and
product strategies, with responsibility for sales, ma... |
| 12/07/09 | Affymetrix to Webcast Presentation at the 23rd NASDAQ OMX Investor Forum| SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 25, 2009--
Affymetrix, Inc. (NASDAQ:AFFX) today announced that John Batty,
Executive Vice President and Chief Financial Officer, will present a
company update at the NASDAQ OMX 23rd Investor Program in
London on Tuesday, December 1, 2009, at 1:15 PM GMT.
To access the live and archived webcast, please visit www.affymetrix.com
and click on the "Investors" link under the “Resources for” dropdown
... |
| 11/25/09 | Developing Countries Sign up for Pharmacogenomics for Every Nation Initiative Using the Affymetrix DMET(TM) Plus Panel| SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 27, 2009--
Affymetrix, Inc. (Nasdaq:AFFX) announced today that the Institute for
Pharmacogenomics and Individualized Therapy (IPIT) at the University of
North Carolina in Chapel Hill is using the company’s DMET™ Plus
biomarker panel to expand the Pharmacogenetics for Every Nation
Initiative (PGENI). The PGENI’s mission is to help developing countries
use genetic information to improve their drug dosing decis... |
| 10/27/09 | Affymetrix Reports Third Quarter 2009 Results|
– Company Reports Total Revenue of $78.2 Million and Net Loss of $8.8
Million –
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 21, 2009--
Affymetrix Inc., (NASDAQ:AFFX) today reported its operating results for
the third quarter of 2009. Total revenue for the quarter was $78.2
million, as compared to total revenue of $75.2 million in the third
quarter of 2008. In constant currency terms, the third quarter of 2009
was negatively impacted by ... |
| 10/21/09 | Affymetrix Announces Major Genotyping Project With Kaiser Permanente and the University of California at San Francisco for NIH-Funded Epidemiology Study|
100,000-Sample Study to Be Performed Using New Axiom™ Genotyping
Solution
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 14, 2009--
Affymetrix, Inc. (Nasdaq:AFFX) today announced that the Kaiser
Permanente Research Program on Genes, Environment, and Health (RPGEH)
and the University of California at San Francisco (UCSF) have entered
into an agreement with Affymetrix to support genome-wide analyses of DNA
samples from 100,000 Kaiser Permane... |
| 10/14/09 | Affymetrix Launches New Platform for Next-Generation Genotyping|
The Axiom™ Genotyping Solution Expands Content, Throughput, and
Customizable Arrays on a Single Platform
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 14, 2009--
Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom
Genotyping Solution, its next-generation array technology designed to
match the significant rise in genetic content generated by government
and privately funded sequencing projects. This high-throughput,
autom... |
| 10/14/09 | Affymetrix to Host Conference Call on October 21, 2009 to Announce Third Quarter 2009 Results| SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 7, 2009--
Affymetrix, Inc. (Nasdaq:AFFX) today announced that it will release
operating results for the third quarter of 2009 after close of the stock
market on Wednesday, October 21, 2009.
Affymetrix' management team will host a conference call on October 21,
2009 at 2:00 P.M. PT to review its operating results for the third
quarter of 2009. A live webcast can be accessed by visiting the Investor
... |
| 10/07/09 | Affymetrix to Webcast Presentations at September Financial Conferences| SANTA CLARA, Calif. & ORANGE COUNTY, Calif.--(BUSINESS WIRE)--Sep. 1, 2009--
Affymetrix, Inc. (Nasdaq: AFFX) today announced that company management
will provide a corporate overview at four conferences in September.
John Batty, Executive Vice President and CFO, will present at the
following conferences:
Robert W. Baird Healthcare Conference, New York, NY, on Wed., Sept. 9
at 8:30 am ET
Thomas Weis... |
| 09/01/09 | Affymetrix and Beckman Coulter Join Forces to Provide Robust, Automated Target Preparation Solutions| SANTA CLARA, Calif. & ORANGE COUNTY, Calif.--(BUSINESS WIRE)--Aug. 26, 2009--
Affymetrix, Inc. (Nasdaq: AFFX) and Beckman Coulter, Inc. today
announced that they have entered into an agreement to offer researchers
co-developed products from the market leaders in microarrays and
automated liquid handlers. The collaboration will provide scientists
with optimized, robust solutions for genomic research, fortified by
end-to-end support.
The... |
| 08/26/09 | The NIAID-Supported Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute Offers New Affymetrix Array for Faster Identification of E. Coli and Shigella| Custom Microarray Allows Scientists to Identify Different Strains of the Potentially Fatal Foodborne Pathogens
SANTA CLARA, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 5, 2009--
Affymetrix, Inc. (Nasdaq:AFFX) and the National Institute of Allergy and
Infectious Diseases (NIAID)-supported Pathogen Functional Genomics
Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI) today
announced the launch of the Affymetrix FDA-ECSG custom microarray for
... |
| 08/05/09 | Affymetrix Reports Second Quarter 2009 Results| -- Company reports total revenue of $81.6 million and net income of $7.3
million --
SANTA CLARA, Calif., July 22 /PRNewswire-FirstCall/ -- Affymetrix Inc.,
(Nasdaq: AFFX) today reported its operating results for the second quarter of
2009. Total revenue for the quarter was $81.6 million, as compared to total
revenue of $86.9 million in the second quarter of 2008. The negative currency
impact for the quarter was $3.0 million.
Product r... |
| 07/22/09 |
|
